🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Discover SAB-142: a breakthrough fully-human anti-thymocyte globulin treatment for #Type1Diabetes (T1D). Clinically validated and effective in delaying T1D onset. Learn more: onlinexperiences.com/scripts/Server… #SABBio #Type1Diabetes #Therapeutics #Immunology #Biopharma #Biotech

Our groundbreaking therapy, #SAB142, is the first fully-human anti-thymocyte #therapeutic that can be administered multiple times without inducing unwanted immune reactions. With potential benefits for millions living with #Type1Diabetes, learn more: fal.cn/3z7Gu #T1D

Watch the replay of #SABRnD Day featuring our #Type1Diabetes therapeutic, SAB-142, our first-in-class fully-human Anti-Thymocyte Globulin (ATG) treatment aimed to provide superior safety & efficacy for delaying onset or progression of T1D: fal.cn/3z9KV #Biotech #$SABS

Promising news for the future in Type 1 Diabetes disease-modifying treatments! We’re proud to share positive results from our recent GLP toxicology study for SAB-142, a novel immunotherapy for #Type1Diabetes, at #FOCIS2023 this week. Read more: fal.cn/3zioc

Our fully-human immunoglobulins (hIgGs) are a breakthrough in immunotherapy. Derived from patented TcBovine hyperimmunization, they target complex diseases with multiple dysregulated pathways. Explore their potent potential: fal.cn/3zlED #SABBio #Immunology #Biotech

Happy Independence Day! The fourth of July is a day of freedom to express our pride in being a nation of hope and prosperity. Praying for safety and good health for our fellow citizens.

We're revolutionizing Type 1 Diabetes treatment with SAB-142, a fully-human, multi-target anti-thymocyte immunoglobulin treatment for #T1D. Explore the science behind our breakthrough: fal.cn/3zFPS #SABBio #Innovation #Therapeutics #Immunology #Biopharma

#DiversitAb produces fully-human immunoglobulin #hIgG antibodies in a way that mimics the human immune response. With the potential to target multiple modes of action, discover how #SABBio's platform is leading the way in fully-human antibody therapies: fal.cn/3zPzD

SAB-142 takes #T1D treatment to new heights by providing a multi-pathway approach that can be administered as a single #therapeutic. Learn how we're working to change the trajectory of #Type1Diabetes: fal.cn/3zRpZ

#SABBio fully-human immunoglobulins (hIgGs) are a breakthrough in immunotherapy. Derived from our patented Tc Bovine, they target complex diseases with multiple dysregulated pathways. See how: fal.cn/3A10A #Immunology #Therapeutics #Biotech

No serum sickness or anti-drug antibodies! #SAB142's fully-human antibodies garner native recognition, ensuring a seamless #Type1Diabetes #therapeutic experience. GLP toxicology study confirms its a well-tolerated multi-target therapy for #T1D: fal.cn/3A5d3

Join SAB BIO $SABS for an R&D webinar on Tues, Jan. 28 at 8am ET with T1D key opinion leader Michael Haller, MD (University of Florida) to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. Register here: lifescievents.com/event/sab-bio/

Have you registered to learn about our topline clinical trial results for T1D therapy SAB-142 tomorrow? Jan 28 8:00am EST - registry link: lifescievents.com/event/sab-bio/

Today we announce positive topline data for our Ph 1 clinical trial results for SAB-142, our potentially disease-modifying therapy for T1D. Learn more at our press release here: ir.sab.bio/news-releases/…

$SABS CEO will join the Guggenheim SMID Cap Biotech Conference next week on Feb 6 at 2pm for a fireside chat to chat SAB-142. Watch it here: wsw.com/webcast/guggen…

Our CEO Sam Reich chats SAB-142 and diabetes with the Big Biz Show in San Diego. Thanks for having $sabs on air! Airing on various networks, watch the video here: vimeo.com/1053059299

COMING UP FEB 12: $SABS CEO will be joining Oppenheimer Health Conf on Feb 12 at 10:00am EST fireside. Webcast Link: wsw.com/webcast/oppenh…

Quick clip from a recent interview $SABS CEO Sam Reich did on a return visit with Big Biz Show explaining what SAB-142 might do for T1D patients, if approved.

Major news this morning for $SABS - we've raised an oversubscribed $175M PIPE which will fully fund pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of T1D in newly diagnosed patients. More info at link: ir.sab.bio/news-releases/…